A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Dalbavancin (Primary) ; Linezolid; Vancomycin
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms DISCOVER-1
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data fro four phase III stuadies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 30 Oct 2016 Pooled results of this and other 3 trial (VER001-9, DUR001-302 and DUR001-303) presented at the IDWeek 2016
    • 02 Mar 2015 According to an Actavis media release, the EC has granted Actavis' subsidiary Durata Therapeutics International B.V. marketing authorization for XYDALBA for the treatment of acute bacterial skin and skin structure infections in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top